Max Planck Institute for Human Cognitive and Brain Sciences, 04103 Leipzig, Germany.
J Affect Disord. 2011 Nov;134(1-3):32-8. doi: 10.1016/j.jad.2010.11.008. Epub 2010 Dec 8.
Mood disorders are characterized by specific glial pathology. Recently, based on histopathological post mortem studies, the glial hypothesis has been discussed as a dynamic process, in particular with regard to glioplasticity. Whereas in young subjects with mood disorders, glial cell density or glial cell numbers are reduced, they are increased in elderly subjects.
To validate this concept in vivo, we investigated the dynamic course of glial pathology in mood disorders across studies measuring the glial marker protein S100B in serum in a systematic and quantitative meta-analysis according to the QUOROM and PRISMA statement. We searched for studies in PubMed and Medline, applied strict inclusion/exclusion criteria, and calculated effect sizes according to Cohen and Hedges.
The final meta-analysis included 174 subjects with mood disorders and 102 control subjects. It demonstrated higher levels of the glial marker protein S100B in older compared with younger adult subjects suffering from mood disorders, although both young and older subjects showed elevated values in comparison to control subjects. Illness duration and age at onset had no impact on serum S100B.
Influences of antidepressive drugs vs. the spontaneous course of the illness, differences between mood disorder subtypes and the specific role of S100B have to be investigated in future longitudinal studies.
The meta-analysis indicates a modifying effect of S100B in mood disorders in the interaction with age, with an increasing role across the lifespan. Results are relevant for the understanding of mood disorders and future illness modifying therapies because S100B may influence neuro- and glioplasticity.
情绪障碍的特征是特定的神经胶质病理学。最近，基于组织病理学的尸检研究，神经胶质假说被认为是一个动态的过程，特别是与神经可塑性有关。而在年轻的情绪障碍患者中，神经胶质细胞密度或数量减少，而在老年患者中则增加。
为了在体内验证这一概念，我们根据 QUOROM 和 PRISMA 声明，对血清中神经胶质标志物 S100B 进行了系统和定量的荟萃分析，研究了情绪障碍中神经胶质病理学的动态过程。我们在 PubMed 和 Medline 中进行了搜索，应用了严格的纳入/排除标准，并根据 Cohen 和 Hedges 计算了效应大小。
最终的荟萃分析纳入了 174 名患有情绪障碍的患者和 102 名对照者。它表明，与年轻的成年情绪障碍患者相比，老年患者的神经胶质标志物 S100B 水平更高，尽管年轻和老年患者与对照组相比均显示出升高的值。疾病持续时间和发病年龄对血清 S100B 没有影响。
未来的纵向研究需要调查抗抑郁药物与疾病自发过程、情绪障碍亚型之间的差异以及 S100B 的具体作用。
荟萃分析表明，S100B 在情绪障碍中存在修饰作用，与年龄相互作用，在整个生命周期中发挥着越来越重要的作用。这些结果与情绪障碍的理解和未来的疾病修饰治疗有关，因为 S100B 可能影响神经和神经胶质可塑性。
